Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 7;72(14):1217-22.
doi: 10.1212/01.wnl.0000345668.03039.90.

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

P L Nghiemphu  1 , W Liu, Y Lee, T Than, C Graham, A Lai, R M Green, W B Pope, L M Liau, P S Mischel, S F Nelson, R Elashoff, T F Cloughesy
Affiliations

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

P L Nghiemphu et al. Neurology. .

Abstract

Objective: Bevacizumab has been shown to be effective in the treatment of recurrent glioblastoma in combination with chemotherapy compared with historic controls but not in randomized trials.

Methods: We conducted a retrospective analysis of patients treated for recurrent glioblastoma with bevacizumab vs a control group of patients, comparing progression-free survival (PFS) and overall survival (OS) between the two groups, and performed subgroup analysis based on age and performance status. Expression of vascular endothelial growth factor (VEGF) based on age was examined using DNA microarray analysis. We also evaluated the impact of bevacizumab on quality of life.

Results: We identified 44 patients who received bevacizumab and 79 patients who had not been treated with bevacizumab. There was a significant improvement in PFS and OS in the bevacizumab-treated group. Patients of older age (> or =55 years) and poor performance status (Karnofsky Performance Status < or =80) had significantly better PFS when treated with bevacizumab, and bevacizumab-treated older patients had significantly increased OS. VEGF expression was significantly higher in older glioblastoma patients (aged > or =55 years). Patients treated with bevacizumab also required less dexamethasone use and maintained their functional status longer than the control group.

Conclusions: Bevacizumab in combination with chemotherapy may be a more effective treatment for recurrent glioblastoma and warrants further randomized prospective studies to determine its effect on survival. Bevacizumab also has more effect in those with older age and might reflect biologic differences in glioblastoma in different age groups as seen with the expression of vascular endothelial growth factor.

PubMed Disclaimer

Figures

None
Figure 1 Kaplan–Meier survival curves for all patients (A) Progression-free survival and (B) overall survival of bevacizumab-treated patients vs control group.
None
Figure 2 Kaplan–Meier survival curves by age (A) Progression-free survival for patients aged <55 years, (B) progression-free survival for patients aged ≥55 years, (C) overall survival for patients aged <55 years, and (D) overall survival for patients aged ≥55 years.
None
Figure 3 Vascular endothelial growth factor (VEGF) expression by age via DNA microarray analysis
None
Figure 4 Quality-of-life analysis (A) Percent change in dexamethasone from baseline in bevacizumab (Bev)–treated group (top) and control group (bottom) from the start of treatment to 1 month after failure. (B) Time to dexamethasone increase in control vs bevacizumab-treated group. (C) Time to decrease in Karnofsky Performance Status between control vs bevacizumab-treated group.
See this image and copyright information in PMC

References

    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996. - PubMed
    1. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the New Approaches to Brain Tumor Therapy CNS Consortium phase I and II clinical trials. J Clin Oncol 2007;25:2601–2606. - PMC - PubMed
    1. Lamborn KR, Yung WKA, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neurooncology 2008;10:162–170. - PMC - PubMed
    1. Wong E, Hess K, Gleason M, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572. - PubMed
    1. Carlson MRJ, Pope WB, Horvath S, et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007;13:2592–2598. - PubMed

Publication types

MeSH terms